34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis
Saved in:
Published in | Journal of the American Academy of Dermatology Vol. 87; no. 3; p. AB123 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.09.2022
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0190-9622 1097-6787 |
---|---|
DOI: | 10.1016/j.jaad.2022.06.525 |